| abstract |
Novel spiro-quinolone hydantoin derivatives useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications are disclosed. Pharmaceutical compositions containing the novel compounds and a method of treating chronic diabetic complications are also disclosed. Preferred compounds include spiro[2,3-dihydro-1H,5H-benzo[ij]quinolizin[1,4']imidazolidin]-2',5,5= -trione and 10-chloro-spiro[2,3-dihydro-1H,5H-benzo[ij]quinolizin[1,4']imidazolidi n]-2',5,5'-trione.n[US4193996A] |